Match!
Christopher Sweeney
Harvard University
519Publications
59H-index
12.7kCitations
Publications 519
Newest
#1S. GillessenH-Index: 8
#2Laurence Collette (European Organisation for Research and Treatment of Cancer)H-Index: 70
Last.Ugo De GiorgiH-Index: 33
view all 0 authors...
#1Anis Hamid (Harvard University)H-Index: 2
#2Kathryn J. Gray (Harvard University)H-Index: 14
Last.Christopher Sweeney (Harvard University)H-Index: 59
view all 7 authors...
Abstract Background PTEN deletion is associated with relapse after therapy for localized prostate cancer. There are limited data on PTEN loss as detected by immunohistochemistry (IHC) and the risk of lethal disease after surgery. Objective To determine whether PTEN loss as detected by quantitative fluorescence IHC (FIHC) predicts lethal disease outcomes after surgery for prostate cancer. Design, setting and participants We used formalin-fixed, paraffin-embedded radical prostatectomy specimens to...
#1Edoardo Francini (Harvard University)H-Index: 11
#2Kathryn J. Gray (Harvard University)H-Index: 14
Last.Christopher Sweeney (Harvard University)H-Index: 59
view all 9 authors...
In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer therapies on the OS of patients with mCRPC. Two cohorts of patients diagnosed with mCRPC between 2004 and 2007, treated with drugs used in the limited treatment era only (A), and between 2010 and 2013, treated al...
#1S. Prast‐Nielsen (KI: Karolinska Institutet)H-Index: 1
#2Anne-Marie Tobin (KI: Karolinska Institutet)H-Index: 16
Last.Lionel Fry (Imperial College London)H-Index: 51
view all 9 authors...
12345678910